13 recruiting, 12 completed, 4 active not recruiting, 3 withdrawn. 11 Phase 2, 10 Not applicable, 6 Phase 1, 3 Early Phase 1, 2 Phase 3.
Follow Bone Sarcoma: new trials by email Literature Review of Bone Sarcoma trials Research Report on Bone Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bridging Adolescent and Young Adult Sarcoma Survivors With Personalized Oncology Exercise Service (AYA-ONE): A Pilot Intervention Exercise Triage and Personalized Exercise Program - Sarcoma, Bone Sarcoma | Not applicable | Recruiting | Dana-Farber Cancer Institute | 40 | 2026-08-01 | 2026-08-26 |
| "Exercise Intervention to Increase Physical Activity in Young Sarcoma Survivors (Sport Ist Herzenssache)" Individualized Exercise Program - Bone Sarcoma, Soft Tissue Sarcoma (STS) | Not applicable | Not yet recruiting | Universität Duisburg-Essen | 46 | 2026-08-01 | 2026-07-27 |
| Preoperative Immunonutrition in Patients With Bone and Soft Tissue Sarcomas Forticare Advanced oral nutritional supplement - Bone Sarcoma, Soft Tissue Sarcoma | Not applicable | Recruiting | St. Anne's University Hospital Brno, Czech Republic | 100 | 2026-04-01 | 2026-05-27 |
| XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma Biospecimen Collection, Computed Tomography, Echocardiography - Metastatic Leiomyosarcoma, Unresectable Leiomyosarcoma | Phase 2 | Recruiting | Northwestern University | 73 | 2024-09-19 | 2026-10-13 |
| Evaluation of Tumor Resection Guided by Intraoperative Indocyanine Green Dye Fluorescence Angiography in Patients With Sarcoma Non-Interventional Study - Bone Sarcoma, Soft Tissue Sarcoma | Recruiting | Mayo Clinic | 75 | 2024-03-14 | 2026-08-04 | |
| Study Assessing the Effects of Early Psychiatric Referral on Mental Health and Quality of Life in People With Sarcoma referral to the Memorial Sloan-Kettering Cancer Center (MSK) Department of Psychiatry and Behavioral Sciences. - Sarcoma, Bone Sarcoma | Not applicable | Recruiting | Memorial Sloan Kettering Cancer Center | 60 | 2023-11-07 | 2026-05-15 |
| A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma Cyclophosphamide, attIL2-T cells - Soft Tissue Sarcoma, Bone Sarcoma | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 5 | 2023-09-08 | 2026-08-18 |
| Culturally Adapted Mobile Treatment of Chronic Pain in Adolescent Survivors of Pediatric Cancer Cognitive Behavior Therapy, Transcranial Direct Current Stimulation, Placebo Administration - Bone Sarcoma, Childhood Cancer | Not applicable | Completed | St. Jude Children's Research Hospital | 68 | 2023-04-06 | 2026-02-04 |
| In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Poly ICLC, Radiation Therapy - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 1 | Active not recruiting | University of Southern California | 14 | 2023-01-09 | 2026-06-18 |
| Gemcitabine With Ascorbate Including Adolescents Ascorbate, Gemcitabine - Soft Tissue Sarcoma, Bone Sarcoma | Early Phase 1 | Withdrawn | David Dickens | 2023-01-01 | 2023-02-22 | |
| Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas Osteosarcoma, Bone Tumor | Not yet recruiting | Klinikum Stuttgart | 1000 | 2022-09-01 | 2022-08-25 | |
| Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma Gemcitabine, 9-ING-41, Docetaxel - Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma | Phase 2 | Withdrawn | Brown University | 2022-03-01 | 2021-12-07 | |
| Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone Electronic Health Record Review, Quality-of-Life Assessment - Bone Sarcoma, Chondrosarcoma | Recruiting | Mayo Clinic | 72 | 2022-01-20 | 2026-03-13 | |
| Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance Fruquintinib - Bone Sarcoma, Soft Tissue Sarcoma | Completed | Peking University People's Hospital | 124 | 2021-11-25 | 2024-01-17 | |
| Assessment of the Functional Outcome and Quality of Life in Sarcoma Patients Functional outcome, Health related quality of life (HRQoL) assessment - Soft Tissue Sarcoma, Bone Sarcoma | Not applicable | Recruiting | Universitaire Ziekenhuizen KU Leuven | 60 | 2021-10-01 | 2026-03-16 |
| A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Gemcitabine, Docetaxel, 9-ING-41 - Sarcoma, Soft Tissue Sarcoma | Phase 2 | Withdrawn | Brown University | 2021-09-01 | 2021-07-28 | |
| Exercise Intervention for Bone Tumor Patients Exercise therapy, Information - Bone Sarcoma | Phase 2 / Phase 3 | Completed | Universität Duisburg-Essen | 11 | 2021-08-07 | 2024-12-06 |
| Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients Treatment by regorafenib and best supportive care - Bone Sarcoma, Osteosarcoma | Phase 2 | Recruiting | Centre Leon Berard | 36 | 2021-07-21 | 2026-02-17 |
| Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas dinutuximab beta - Bone Sarcoma, Embryonal Rhabdomyosarcoma | Phase 3 | Recruiting | N.N. Petrov National Medical Research Center of Oncology | 40 | 2021-05-20 | 2024-11-01 |
| Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot) Ascorbate - Sarcoma, Soft Tissue Sarcoma | Early Phase 1 | Active not recruiting | University of Iowa | 30 | 2020-11-24 | 2026-05-22 |
Showing 20 of 37. Sign in to see all of them.
Bone Neoplasms (37) · Sarcoma (27) · Osteosarcoma (12) · Sarcoma, Ewing (7) · Chondrosarcoma (6) · Histiocytoma, Malignant Fibrous (6) · Leiomyosarcoma (5) · Hemangiosarcoma (4) · Sarcoma, Synovial (4) · Rhabdomyosarcoma (3) · Chordoma (2) · Dermatofibrosarcoma (2) · Gastrointestinal Stromal Tumors (2) · Liposarcoma (2) · Motor Activity (2)
Bone Diseases (37) · Musculoskeletal Diseases (37) · Neoplasms by Site (37) · Neoplasms (35) · Neoplasms by Histologic Type (35) · Neoplasms, Connective and Soft Tissue (35) · Neoplasms, Connective Tissue (16) · Neoplasms, Bone Tissue (13) · Sarcoma (8) · Neoplasms, Muscle Tissue (7) · Histiocytoma (6) · Neoplasms, Fibrous Tissue (6) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Myosarcoma (4)
Gemcitabine (5) · Nivolumab (3) · 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (2) · Ascorbic Acid (2) · Cyclophosphamide (2) · Docetaxel (2) · Doxorubicin (2) · Ipilimumab (2) · pembrolizumab (2) · Aspirin (1) · Behavioral Sciences (1) · Blood Component Removal (1) · CTLA-4 Antigen (1) · Cisplatin (1) · Cognitive Behavioral Therapy (1)
M.D. Anderson Cancer Center (3) · Brown University (2) · Centre Leon Berard (2) · Grupo Espanol de Investigacion en Sarcomas (2) · Massachusetts General Hospital (2) · Mayo Clinic (2) · Memorial Sloan Kettering Cancer Center (2) · University of Southern California (2) · Universität Duisburg-Essen (2) · Assaf-Harofeh Medical Center (1) · Dana-Farber Cancer Institute (1) · David Dickens (1) · Heike E Daldrup-Link (1) · Klinikum Stuttgart (1) · Macarena De La Fuente, MD (1)
United States (22) · France (3) · China (2) · Italy (2) · Spain (2) · United Kingdom (2) · Argentina (1) · Belgium (1) · Brazil (1) · Canada (1) · Costa Rica (1) · Czechia (1) · Germany (1) · Ireland (1) · Mexico (1)
Alba Rubio (1) · Amir A Jazaeri (1) · Antonio Casado (1) · Beatrice Seddon, Ph.D., M.D (1) · Bradford S. Hoppe, MD, MPH (1) · Bradley D DeNardo, MD (1) · Bradley DeNardo, MD (1) · Chao Cao, MD (1) · Claudia Valverde (1) · Cristina Mata (1) · Daniel Prince, MD (1)
PMID 31401903, PMID 28988646, PMID 31902458, PMID 33203665, PMID 35115306, PMID 36290890, PMID 39122389, PMID 39356980, PMID 41836677
P30CA014089 (1), P30CA060553 (1), R61CA280978 (1)